As of June 8, 2025, Ultimovacs ASA (ULTI.OL) reports a Net Margin of -245.41%.
Net Margin shows the share of revenue that becomes profit after all costs, reflecting overall profitability.
Historical Trend of Ultimovacs ASA's Net Margin
Over recent years, Ultimovacs ASA's Net Margin has shown limited historical data. The table below summarizes the historical values:
| Date | Net Margin |
|---|---|
| 2024-12-31 | -245.41% |
| 2023-12-31 | -245.41% |
This trend highlights how Ultimovacs ASA manages its overall profitability and cost control over time.
Comparing Ultimovacs ASA's Net Margin to Peers
To better understand Ultimovacs ASA's position, it's useful to compare its Net Margin against industry peers. Below are selected comparisons:
| Company | Net Margin |
|---|---|
| Ultimovacs ASA (ULTI.OL) | -245.41% |
| Vaccibody AS (VACC.OL) | 69.66% |
| Arcticzymes Technologies ASA (AZT.OL) | 8.12% |
| Hofseth Biocare ASA (HBC.OL) | -48.68% |
| PCI Biotech Holding ASA (PCIB.OL) | -243.76% |
| Lytix Biopharma AS (LYTIX.OL) | -846.64% |
Compared to its competitors, Ultimovacs ASA's Net Margin is about average compared to peers, reflecting typical industry profitability.